Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
11 Sep 2017 ESMO 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: First-line Dabrafenib and Trametinib Shows Substantial Clinical Activity in BRAF V600E–mutated Metastatic NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017 Press Release: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma Melanoma and other skin tumours
11 Sep 2017 ESMO 2017 Press Release: Combination Targeted Adjuvant Therapy Doubles Relapse-free Survival in Stage III Melanoma Melanoma and other skin tumours
11 Sep 2017 ESMO 2017 Press Release: Debate on Duration of Colon Cancer Adjuvant Chemotherapy Takes Centre Stage at ESMO 2017 Gastrointestinal cancers
11 Sep 2017 ESMO 2017 Press Release: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer Head and neck cancers
10 Sep 2017 ESMO 2017: First KEYNOTE-028 Report of Pembrolizumab Activity in Patients with PD-L1-positive pNETs and Carcinoid Tumours Endocrine and neuroendocrine tumours - Cancer Immunology and Immunotherapy
10 Sep 2017 ESMO 2017: Immune Landscape of PanNETs Endocrine and neuroendocrine tumours - Pathology/Molecular biology
10 Sep 2017 ESMO 2017: Improved Survival Demonstrated with NSCLC-chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma with RB1 Wild-type Endocrine and neuroendocrine tumours - Translational research
10 Sep 2017 ESMO 2017: Pembrolizumab Continues to Show Greater Benefit over Chemotherapy in Recurrent, Advanced Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
10 Sep 2017 ESMO 2017: Location of the Primary Tumour, but not KRAS Mutations, May Indicate SIRT Survival Benefit in mCRC Gastrointestinal cancers
10 Sep 2017 ESMO 2017: Combined Abemaciclib with NSAI Show Significant Clinical Benefit as Initial Treatment for Patients with HR-positive/HER2-negative ABC at Interim Analysis Breast cancer - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Ramucirumab Improves PFS in Patients with Platinum Refractory Advanced Urothelial Carcinoma Genitourinary cancers - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy